Unlike common nutraceuticals stocked in every health store, CJC-1295 moves through a global research peptide market that Nili residents navigate through international suppliers. This global online supply model is actually an advantage for quality — top vendors differentiate through analytical documentation in ways brick-and-mortar outlets simply cannot. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. This guide guides Nili researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Nili comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Vetting CJC-1295 vendors requires starting from the COA: request the batch-specific certificate prior to buying, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. For Nili researchers evaluating vendors with limited track records: a small initial order to verify quality before committing to research quantities is standard practice in the community. Keep lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order CJC-1295 — ships to Nili
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that rigorous vendor evaluation eliminates. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
